Hikma Pharmaceuticals Plc Injectables Analyst and Investor Day USA (4549O)

TIDMHIK

RNS Number : 4549O

Hikma Pharmaceuticals Plc

11 October 2012

Hikma Injectables Analyst and Investor Day

London, 11 October 2012- Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group, is today hosting a site visit for analysts and investors in Cherry Hill, New Jersey. The visit will include a tour of its recently acquired Multi-Source Injectables ("MSI") manufacturing facility and management will be giving a series of presentations on Hikma's global Injectables business.

In the year to date, Hikma's Injectables business has delivered strong organic growth across the US, Europe and the MENA region. This performance has been driven by new product launches, increased tender sales, better portfolio management, new contract wins, more efficient manufacturing and increased demand from continuing product shortages in the US. In August, Hikma announced a 94% increase in revenues to $225.2 million and adjusted EBIT margin of 22.0% for the six months ended 30 June 2012. At this time, the company stated that the first half performance was expected to be sustained in the second half of the year. Hikma reiterates this view and continues to see strong potential for its global Injectables business in the coming years.

Said Darwazah, Chief Executive Officer of Hikma, said: "We are delighted with the performance of our global Injectables business, which has been transformed by the acquisition of MSI. Our track record of investing in our high quality manufacturing facilities and product portfolio is helping to drive the excellent growth seen so far this year and we remain very optimistic about the prospects for our global Injectables business both in the short and longer term."

A live webcast and presentation slides will be available at 9am EST / 2pm GMT on Hikma's website. Please follow this link to view the event: http://www.hikma.com/en/investors/analyst-investor-day.aspx

-- ENDS --

Enquiries:

 
  Hikma Pharmaceuticals PLC 
  Susan Ringdal 
   Vice President, Corporate Strategy                +44 (0)20 
   and Investor Relations                             7399 2760 
 
   FTI Consulting Ben Atwell/Julia Phillips/Jonathan 
      Birt/Matthew Cole                    +44 (0)20 7831 3113

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918.0 million and profit attributable to shareholders of $80.1 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCMBBTTMBJBMJT

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024